Insights from the Midwest Reproductive Symposium: Clinical utility of SpermQT real-world data

Andy Olson, Co-founder & CEO, Inherent Biosciences | Path Fertility

At the Midwest Reproductive Symposium in Chicago, we had the distinct honor of presenting a scientific poster that marks a significant advancement in the field of fertility treatments. Our presentation focused on SpermQT, our innovative epigenetic sperm quality test, and the compelling new real-world data collected from 25 reproductive endocrinologists across 11 clinics.

The Power of Collaboration

The gathering in Chicago was not just a showcase of scientific data, but a celebration of collaborative spirit in the reproductive health community. Each discussion, whether with a peer, a mentor, or an industry partner, was a thread in the rich tapestry of shared knowledge and mutual goals. Our real-world findings on the clinical utility of SpermQT sparked conversations that extend beyond the confines of the symposium, highlighting the test’s potential to transform male fertility diagnostics.

Groundbreaking Data, Promising Futures

The data we presented underscores a critical breakthrough in understanding male fertility through sperm epigenetics. The data show a decrease in Intrauterine Insemination (IUI) pregnancy rates in men with Abnormal SpermQT results irrespective of their sperm total motile count. This suggests that SpermQT is identifying sub-fertility in men with normal semen parameters - meaning there are plenty of motile sperm present, however the sperm can’t find, bind, penetrate and fertilize an egg. The clinical utility demonstrated by SpermQT offers a new layer of insight, empowering physicians to provide personalized and effective infertility treatments.

Gratitude and Looking Forward

The enthusiasm and feedback from the community have been overwhelmingly positive. We are deeply grateful for the insightful suggestions and robust engagement from everyone who attended. Their shared perspectives not only enrich our work but also propel us forward with renewed vigor.

As we continue our mission to raise the standard of care, our commitment remains strong—to innovate, to enlighten, and to enhance the journey to parenthood for couples worldwide. The road ahead is promising, and together, we are setting new standards in reproductive health.

Thank you to all our collaborators and supporters. Your partnership is pivotal as we pioneer new paths in fertility diagnostics.